US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.605
  • +0.005+0.82%
Close Dec 20 16:00 ET
  • 0.592
  • -0.013-2.12%
Post 20:01 ET
154.78MMarket Cap-3.62P/E (TTM)

Adaptimmune Therapeutics Key Stats

Adaptimmune Therapeutics Q3 2024 Earnings Date

Currency:USDNov 13, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
20.49M
40.90M
+20.41M
Beat Est.
+179.94%
+458.83%
+99.63%
EPS
-0.08
-0.06
+0.02
Beat Est.
-160.54%
+66.67%
+22.98%
Buy

Dec 22, 2024

Adaptimmune Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.300M--
--2024/Q4-- / 8.828M--
Nov 13, 20242024/Q340.901M / 20.489M--
Aug 12, 20242024/Q2128.231M / 44.762M--
May 15, 20242024/Q15.678M / 20.480M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.300M--
--2024/Q4-- / 8.828M--
Nov 13, 20242024/Q340.901M / 20.489M--
Aug 12, 20242024/Q2128.231M / 44.762M--
May 15, 20242024/Q15.678M / 20.480M--

Unlock Free Earnings Estimates

Adaptimmune Therapeutics Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Dec 22, 2024

Buy

  • Buy

    71.43%
  • Hold

    28.57%
  • Sell

    0.00%

Price Target

No Data